 - Any concurrent active malignancy requiring treatment other than basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder tumors, other malignancies curatively treated 3 years prior to study entry or patients with adenocarcinoma of the prostate that has been surgically treated and with a post-treatment PSA that is non-detectable. 